If you are looking into psychedelic-assisted treatment in Latvia (for yourself or for someone close to you), the country has, quietly, the strongest access story in the Baltics: an esketamine route paid directly from the state health budget, running since 2025 at the National Mental Health Centre in Riga. Everything else (psilocybin, MDMA, private ketamine clinics) is research-only or absent. This guide covers who qualifies, how the doctors' council route works, what it costs, and what remains unknown; you can begin orienting yourself with our eligibility check.
TL;DR Latvia pays for esketamine therapy for treatment-resistant depression from the state health budget: the National Health Service (NVD) covers roughly €145 per dose and the treatment is free for the patient. The route runs exclusively through a doctors' council (konsilijs) decision at the National Mental Health Centre (NPVC), delivered at three NPVC sites in Riga; 29 patients used it in the first year, and a typical course is 10 to 16 doses. Psilocybin and MDMA are research-only, with no Latvian trial in our tracked data as of July 2026.
At a glance
| Route | Substance | Status in Latvia | Who qualifies | Cost |
|---|---|---|---|---|
| State-paid esketamine | Esketamine (Spravato) | Running since 2025 at NPVC in Riga | Treatment-resistant depression; referral only by doctors' council decision after somatic work-up and symptom-scale assessment | Free for the patient; NVD pays ~€145 per dose |
| Private ketamine clinics | Ketamine | No verified private clinic market | – | – |
| Psilocybin therapy | Psilocybin | Research only | – | – |
| MDMA therapy | MDMA | Research only | – | – |
| Clinical trials | Psilocybin, MDMA, ketamine | No Latvian site in our tracked registry data | Study-specific criteria | Free |
How Latvia compares across the continent: Europe-wide reimbursement map.
State-paid esketamine at NPVC: the first public route in the Baltics
Since 2025, esketamine therapy for treatment-resistant depression is paid by Latvia's National Health Service (Nacionālais veselības dienests): the state pays approximately €145 per dose and the patient pays nothing. In the route's first year, 29 patients received state-paid esketamine at the National Mental Health Centre (NPVC) by mid-August 2025 (NPVC, 15 August 2025). NPVC notes that Latvia is one of the few countries where this therapy is financed directly from the state health budget rather than through an insurer, which, as far as we can verify, makes it the first and only state-funded esketamine route in the Baltics.
Who qualifies and who decides: Referral to state-paid esketamine is possible only by decision of a doctors' council (ārstu konsilijs). Before the council signs off, the patient is assessed thoroughly: somatic examinations, a depression symptom-severity scale, and a review of psychiatric comorbidity risks such as substance use or personality disorders (NPVC). NPVC emphasises the route for severe, complicated depression that threatens day-to-day functioning and needs urgent help. Latvia also has a published clinical pathway for recognising and managing treatment-resistant depression (SPKC algorithm).
What treatment looks like. It is an outpatient procedure: the patient inhales esketamine as a nasal spray in a ward with medical staff present, followed by at least two hours of careful observation. Treatment is combined with a classical oral antidepressant, sessions are more frequent at first and taper depending on response, and an average course runs 10 to 16 doses. Delivery happens at three NPVC sites in Riga: the outpatient centre at Tvaika iela 2 and the Pārdaugava and Veldre clinics (TIEK, 5 September 2025). To see what is listed for Latvia, browse providers in Latvia.
How to start. The practical entry point is psychiatric care, NPVC's patient registration line, with your treatment history in writing: drugs, doses, durations, outcomes. The council decision is the gate, and your documentation is what the council works from.
What we don't know yet
An honest list of the gaps in our verification, as of 30 July 2026:
- The formal eligibility criteria. NPVC describes the assessment, but we have not found a published legal document setting out the exact qualifying criteria or any annual patient quota.
- Waiting times. With 29 patients in the first year, capacity is real but small; we have no data on how long the path from first appointment to council decision takes.
- Whether outside psychiatrists can refer. Public materials describe the route through NPVC's own council; we could not confirm how a patient treated elsewhere in Latvia enters it.
- Any private ketamine market. We have not verified any private ketamine or esketamine clinic operating in Latvia.
Psilocybin and MDMA: research only
Psilocybin and MDMA remain controlled substances in Latvia with no medical-access route (Psychedelic Alpha tracker). Our tracked registry data shows no Latvian psychedelic trial sites; if trial participation matters to you, the realistic option is a site elsewhere in Europe: our trials guide explains how to search and what participation involves. Anyone offering psilocybin or MDMA therapy commercially in Latvia today is operating illegally.
What to expect in treatment
Medically reviewed by Dr. Amy Reichelt, PhD, 31 July 2026: this section and the risks section below.
These routes share a shape (medical screening, supervised administration, structured follow-up), but they are not interchangeable: the indication, the schedule, the staffing and the strength of the evidence all differ depending on whether you are prescribed Spravato (esketamine), given ketamine, or entering a legal psychedelic-assisted therapy route, where your country has one. What every route has in common is where it starts. Treatment begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.
On a Spravato day you self-administer the nasal spray in the practice or clinic under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate, sedation, dissociation, breathing and overall recovery. Dissociation, dizziness, sedation, nausea and a temporary rise in blood pressure are common (though they do not occur in everyone), and settle as the drug clears. You must not drive, operate machinery or undertake anything hazardous until the following day, after a night's sleep, so arrange transport home. Induction is typically more frequent at first and then tapers based on measured response. Under the European label, Spravato for treatment-resistant depression is taken alongside a continuing oral SSRI or SNRI antidepressant.
A ketamine infusion for depression is an off-label use of the drug. It is usually given intravenously over about 40 minutes, with vital-sign and psychological monitoring and a recovery period afterwards. Some services offer ketamine-assisted psychotherapy (KAP), which wraps the dosing in preparation and integration sessions with a therapist; others provide ketamine as a medical antidepressant treatment with no psychotherapy component at all, which is worth establishing before you book. Where a legal psychedelic-assisted therapy route exists, and what that route is depends on the country: a clinical trial in most, a regulated programme or compassionate-use scheme in a few; dosing days are long and closely supervised by trained clinical staff, and sit inside a broader plan of preparation, general psychiatric care and integration. In every setting the medicine is one part of the plan: screening, monitoring and follow-up reduce risk but cannot eliminate it, and psychotherapy or integration may help you make sense of what the treatment brings up and apply it afterwards.
Risks and who should not start
These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:
- Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease. This is a contraindication for Spravato, because of the temporary rise in blood pressure; the other treatments carry their own cardiovascular assessment.
- A personal or family history of psychosis or bipolar disorder: a particular caution for classic psychedelics such as psilocybin, which legal programmes screen for carefully.
- Pregnancy or breastfeeding.
- Current uncontrolled substance use, a history of ketamine misuse, or a high risk of compulsive use: any of these may make treatment inappropriate or require specialist assessment.
A responsible provider screens for all of these before the first dose. Careful screening, monitoring and follow-up reduce risk; they do not remove it. If a clinic is willing to treat you without that assessment, treat it as a warning sign; see our clinic-choice guide. To see who is listed near you, browse providers in Latvia.
Reviewer's note. Ketamine, Spravato (esketamine) and psilocybin-assisted therapies share common elements such as screening, supervision and follow-up, but they should not be presented as interchangeable. Each has distinct indications, contraindications, monitoring requirements and levels of evidence. Spravato follows a regulated treatment pathway, while IV ketamine is generally used off-label and psilocybin therapies remain largely investigational. Importantly, careful screening and clinical monitoring reduce risk but do not eliminate it.
— Dr. Amy Reichelt, PhD, neuroscientist, chartered psychologist and psychotherapist, PsyAccess medical reviewers
Frequently asked questions
Is esketamine therapy really free in Latvia?
Yes, for patients accepted by the doctors' council, the National Health Service pays for treatment (about €145 per dose to the state), and the patient pays nothing. There is no published self-pay route around the council decision.
Who decides whether I qualify?
A doctors' council at NPVC, after somatic examinations, a depression severity-scale assessment and a review of comorbidity risks. Your documented treatment history (what you took, at what dose, for how long, with what result) is the material the council works from.
How long does a course take?
An average course is 10 to 16 doses, given as outpatient sessions with at least two hours of observation each, more frequent at the start and tapering with response, alongside a continuing oral antidepressant.
Can I get psilocybin or MDMA therapy in Latvia?
No. Both are research-only, no Latvian trial is in our tracked data, and no legal clinical route exists. Watch the registries or consider trial sites elsewhere in Europe.
Coming from another country? Whether a clinic will take a non-resident self-pay patient, what a Spravato induction schedule means for a visitor, and where cross-border treatment actually works: ketamine & psychedelic therapy in Europe for international patients.
Sources
- NPVC: 29 patients received state-paid esketamine therapy this year (15 August 2025)
- TIEK: State-paid esketamine therapy — delivery sites and course details (5 September 2025)
- Medikamentu Informācijas Centrs: 29 patients used state-paid therapy for resistant depression
- KVIS: Clinical pathway — recognition, management and care of treatment-resistant depression
- EMA: Spravato (esketamine) EPAR
- Psychedelic Alpha: Worldwide psychedelic laws tracker
- ClinicalTrials.gov
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and coverage rules can change; always verify current requirements with the NVD, NPVC, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.